Core Viewpoint - Merck has appointed Kai Beckmann as the new CEO, set to officially take over from Belén Garijo on May 1, 2026, ensuring a smooth transition while Garijo continues in her role until the end of her term [1][4]. Group 1: Leadership Transition - Belén Garijo has been with Merck for 15 years, leading the pharmaceutical and healthcare business for six years and serving as CEO since 2021. Her key achievements include navigating the company through the COVID-19 pandemic and geopolitical challenges, as well as optimizing the business structure through strategic acquisitions and divestitures [4][5]. - Garijo will continue to focus on the pharmaceutical and healthcare sectors after her tenure, emphasizing her commitment to meeting patient needs [4][5]. - Kai Beckmann has been a member of Merck's executive board since 2011 and has led the high-performance materials business, transforming it into a core enabler in the global semiconductor industry [5][6]. Group 2: Future Outlook - Johannes Bailou, Chairman of the Executive Board and Family Board, highlighted Garijo's leadership in restoring profitability and shaping Merck into a global technology leader. He expressed confidence in Beckmann's vision for technological transformation, which is expected to create significant value for patients, customers, and society [5][6]. - Beckmann's extensive experience in local and global markets is seen as crucial for opening a new chapter for the group, ensuring continuity and normal operations during the transition [5].

Garijo（左）和Beckmann（右） （来源：一度医药） 转自：一度医药 2025年9月25日，默克集团（Merck KGaA）正式宣布，现任电子业务CEO Kai Beckmann将自2026年5月 1日起接任Belén Garijo，担任集团执行董事会主席兼首席执行官。Garijo将按计划在2026年4月底完成任 期，以确保管理层平稳过渡。Beckmann即日起将担任副CEO，并继续负责电子业务直至继任者确定。 Belén Garijo在默克任职15年，其中6年担任医疗健康业务CEO，自2021年起担任集团执行董事会主席兼 CEO。在她的领导下，默克在疫情和地缘政治动荡中保持了稳定发展，通过有机增长和精准并购（如收 购SpringWorks）及资产剥离（如Surface Solutions）推动了可持续增长。 在中国市场，Garijo大力拓展了默克医疗健康业务的布局。此外她还领导了多发性硬化症药物Mavenclad 的全球重新上市和商业化，并完成了三项资产剥离，优化了医疗健康业务组合。卸任后，她将继续活跃 于医疗健康领域，专注于满足患者需求。 Kai Beckmann自1989年加入默克，2011年 ...

Core Viewpoint - Merck has agreed to acquire SpringWorks Therapeutics for $3.9 billion in equity value to enhance its oncology drug business [1][2] Group 1: Acquisition Details - The acquisition price is set at $47 per share, translating to an equity value of approximately $3.9 billion and an enterprise value of about $3.4 billion (30 million euros) after accounting for SpringWorks' cash [1] - The transaction will be funded through available cash and new debt, and is expected to increase Merck's adjusted earnings per share by 2027 [1] Group 2: Strategic Implications - This acquisition marks one of Merck's largest pharmaceutical deals in recent years, reinforcing its ongoing efforts to build a cancer treatment portfolio [2] - Analysts suggest that this deal could accelerate Merck's growth, especially as sales of its cancer drug Bavencio slow down and its multiple sclerosis treatment Mavenclad faces patent expiration [2]